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Despite the recent explosion in RSV vaccine development, there remain substantial hurdles to overcome
before licensing of effective vaccines will allow widespread use, particularly in high-risk populations.
Incomplete understanding of mechanisms and correlates of protection against RSV mean that, for the
time being, successful RSV vaccines must directly demonstrate efficacy, which necessitates large and
costly clinical trials in naturally infected patients. To mitigate the risks inherent in progressing to these
late-stage trials, experimental human RSV infection studies have recently been re-established, represent-
ing the interface between pre-clinical models and observational studies of patients. Not only can they be
used for early proof-of-concept clinical trials to test vaccine efficacy, but human challenge studies also
offer the potential to better understand protective immunity against RSV infection to improve vaccine
design and delivery. In the past, controlled human infection studies with RSV have been instrumental
in elucidating the influence of factors such as route of infection and type of inoculum on the course of
disease. Recently, efficacy trials of novel RSV antiviral drugs have also been successfully undertaken.
Now, with advances in technology, detailed investigations of human mucosal immunity in the RSV-
infected airway are possible. These have indicated defects in RSV-induced humoral and CD8+ T cell
immunity that may contribute to the recurrent symptomatic infection that occurs throughout life and
should be circumvented by optimal vaccines. Here, we discuss the insights derived from RSV human chal-
lenge models; the major impediments to their more widespread uptake; and their potential benefit in
accelerating vaccine development, including future directions to further enhance the relevance of these
models to at-risk patient populations.
Crown Copyright  2016 Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Respiratory syncytial virus (RSV) is the leading cause of infant
respiratory tract infection in the world [1] and a major cause of
morbidity and mortality in elderly adults [2]. Recent research has
also added to a growing literature supporting a causal role for
infant RSV infection in the development of wheeze and asthma
in later life [3]. Despite this huge disease burden, potential for
major impact on global health and decades of research, neither
vaccines nor antivirals are yet available against human RSV. How-
ever, recent advances in understanding of its global epidemiology
and improved antigenic targets have led to an explosion in activity
related to the development of RSV vaccines and therapeutics [4].Nevertheless, while empirical approaches to development may
well lead to effective vaccines, the unique immunobiology of RSV
infection means that many hurdles to success remain, with argu-
ably the biggest barrier to progress being the continued gaps in
our understanding of pathogenesis and protective immunity in
RSV-induced disease.
Whilst controlled RSV infection of laboratory animals provides
mechanistic insights, animal models do not fully recapitulate many
aspects of human disease. Extrapolating from pre-clinical models is
therefore difficult and they remain imprecise guides to under-
standing both mechanisms of protection and pathogenesis, as well
as the likely clinical efficacy of candidate vaccines and therapeutics
[5]. Most animals are at most semi-permissive to human RSV and
require large, supra-physiological inocula to become infected. On
infection, few animals suffer the same clinical syndromes as seen
in humans and none clearly suffer from the recurrent symptoms
on re-infection that is a special feature of human RSV. Furthermore,
although primary infections in animal models have parallels to(2016),
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mechanisms underlying vaccine-enhanced disease, so far none
have been shown to adequately replicate RSV disease in elderly
adults, who become increasingly susceptible to severe disease with
age despite multiple prior infections that induce partial protective
immunity [6]. In contrast, studies of hospitalised children and
high-risk adults allow observations of natural disease in high-risk
patients of greatest interest, but due to the several day incubation
period of the virus coupled with frequent delays in diagnosis, it is
only possible to assess patients as they approach or are recovering
from peak illness [7,8]. While therapeutic trials in hospitalised
children and adults are possible, variability of infecting viruses,
co-infections, co-morbidities, medical interventions and atypical
disease presentations limit interpretation. Robust endpoints for
such trials have yet to be clearly defined, so demonstration of effi-
cacy will be complicated and extremely large clinical trials are
likely to be required for sufficient statistical power in the face of
these confounding factors and low ascertainment rates of certain
patient populations hospitalised with RSV. Development of poten-
tial vaccines and therapeutics in the face of these limitations has
meant long delays with significant associated risks and costs.
Experimental human RSV infection studies therefore offer a
vital complementary approach, allowing controlled study with a
defined viral inoculum, intensive longitudinal sampling and the
opportunity to perform detailed investigations of pre-existing
and pre-symptomatic immune responses as well as induced illness
[9,10]. Human challenge studies have a long history with the inoc-
ulation of James Phipps by Edward Jenner in 1796 regarded as one
of the earliest documented deliberate human infection experi-
ments. Whilst controversial today, such experiments eventually
led to vaccination and the eradication of smallpox nearly two cen-
turies later, arguably one of the greatest triumphs of infectious dis-
ease science. Controlled human infection studies can also provide
unique insights into pathogenesis and immunity, further facilitat-
ing drug and rational vaccine development. Using relatively small
cohorts of volunteers with high attack rates after inoculation, such
studies therefore provide a durable yet relatively rapid and cost-
effective proof-of-concept for evaluation of potential vaccine can-
didates and therapies.
2. Logistical and ethical issues in deliberately infecting with RSV
RSV disease is seldom severe in healthy adults and older chil-
dren, but there remains a theoretical possibility of unexpectedly
severe illness in any experimental infection setting [11]. Further-
more, RSV is transmitted via respiratory droplets and fomites andTable 1
Historical experimental human RSV challenge studies describing numbers of subjects and t
Characteristics and number of
subjects
RSV strain used Main obser
33 males, no history of cardiac,
respiratory or allergic disease
RSV (Long) – wild-type strain
isolated in 1957
High-dose (
antibody in
32 young adults, free of atopic
disease
RSV (A2, wild-type strain isolated
from Australia 1961)
5.2 log TCID
eye and no
105 healthy adults aged
18–50 years
RSS-2 (wild-type strain) (n = 20)
and 4 different ts-mutants (n = 22
per group)
RSS-2 was
cold in 45%
produced s
102 healthy adults aged
18–55 years
RSS-2 (5 subjects challenged with
saline)
Study desig
interferon a
15 young healthy adults with
recent laboratory confirmed
natural RSV infection
RSV A2 Study desig
immunity a
proteins, bu
36 healthy adults aged
18–45 years
RSV A2 (8 subjects challenged
with placebo)
Dose of 4.7
symptoms
correlated w
(mild symp
Please cite this article in press as: Habibi MS, Chiu C. Controlled human infecti
http://dx.doi.org/10.1016/j.vaccine.2016.08.086as such, experimentally-infected individuals pose a potential risk
to others including research staff and the wider public [12]. These
potential risks therefore pose practical and ethical dilemmas that
must be addressed.
One advantage of controlled human infection studies is the abil-
ity to select relatively homogeneous groups of volunteers accord-
ing to pre-defined criteria. In the majority of studies, these are
healthy young adults, who are the least likely to suffer severe dis-
ease and have substantial physiological reserve so that recovery is
swift and complete. However, challenge studies do not need to be
conducted exclusively in healthy young adults; for example, delib-
erate rhinovirus infections of asthmatics and older adults with
chronic obstructive pulmonary disease (who may or may not be
smokers) are ongoing and findings have been highly relevant to
understanding infective exacerbations in these patient groups
[13,14]. As long as the central principle is met that the infection
is either entirely self-limiting or completely treatable with no
long-term sequelae in those studied, it is possible in principle to
study defined individuals with some risk-factors. This criterion is
certainly fulfilled by RSV challenge models, in which hundreds of
individuals have been infected historically (Table 1) and no severe
unexpected adverse events have been reported.
The potential for onward transmission means that research staff
can and should take appropriate precautions with their own health
and use proper personal protective equipment to minimise the
possibility of becoming infected (or, conversely, transmit another
infection to a research participant). Whether the wider public face
a significant additional risk from inoculated research participants
when compared to the natural risk of respiratory viral infections
in everyday life is debatable. Nevertheless, thorough screening of
potential research participants’ social backgrounds to ensure they
do not have any regular contact during the study period with indi-
viduals deemed at high risk of RSV-related complications should be
mandatory. In contrast to experimental challenge with human rhi-
novirus [13] and bacterial pathogens such as Salmonella typhi [15]
(which have all been carried out as out-patient studies), all con-
temporary experimental human RSV challenge studies have been
carried out using in-patient quarantine to further isolate infected
individuals from the community at large for the period of highest
potential infectivity. Whether this is absolutely necessary remains
unclear. Whilst there may be other advantages from the point of
view of experimental control and convenience of obtaining sam-
ples, there is no UK or EU regulation that currently mandates the
use of specific quarantine facilities [10]. The decision regarding
whether to isolate study participants in individual negative-
pressure side-rooms, or to co-house in hospital wards or otherheir characteristics, particular RSV strain used and main observations and conclusions.
vations Year and
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consultation with their local ethics committee. Since the costs of
these facilities may be prohibitively high, flexibility in terms of
quarantine has a profound influence on whether academic groups
can perform these types of studies. If the field is to expand to
address deeper scientific questions about biology and pathogene-
sis, either quarantine capacity will need to be expanded or alter-
nate methods be used, e.g. ambulatory studies with self-isolation.
The latter is attractive from a cost and logistics perspective, and
self-isolation is already used by public health authorities to control
less severe contagious threats (which RSV would not exceed),
although this would require proper scrutiny to ensure due
diligence.
Deliberately infecting human beings, especially with the aim of
inducing illness, has ethical implications. Such experiments would
not normally provide any meaningful benefit to the participants
themselves, so potential harms cannot be justified or offset and
must therefore be minimised. Whilst the development of poten-
tially life-saving interventions against RSV is relevant to all, the
interests of science or society do not override the interests of indi-
vidual participants [16]. Informed consent is crucial to the proper
conduct of infection challenge studies and it is imperative that
potential participants are fully aware of the risks and possible
harms to which they may be exposed. However, informed consent
alone is not sufficient justification for research: there must also be
a limit to the harms that potential participants can be exposed to,
no matter what the perceived societal need. Safety of participants
is of primary concern at all times and screening of potential volun-
teers should be designed to exclude any potential participant
deemed at risk of severe illness.
With respect to RSV, healthy young adults (and even healthy
individuals in the older age group) would at most be expected to
experience a common cold illness. Such illnesses are a part of nor-
mal life and as such, the risk and potential harms of acquiring one
experimental cold is not usually considered significant from an
ethical point of view. The research procedures themselves should
generally be minimally invasive but more invasive sampling, e.g.
bronchoscopy or biopsy may be justified scientifically provided
the frequency of procedures is kept at a minimum. Recently, these
have been permitted on ethical review with assurances that they
are carried out in clinical units with track records of safety and evi-
dence of sufficient staffing and training. These have allowed direct
access to respiratory mucosa, enabling sampling of local immune
cells and epithelia, which is understood to be critical for further
understanding of how to limit respiratory viral disease in man [17].3. Historical RSV challenge studies
In 1961, Kravetz et al. first successfully infected twenty adult
volunteers with an RSV strain isolated in 4 years before from a
patient with bronchopneumonia [18]. Since that time there have
been numerous challenge studies of human RSV involving over
300 subjects using both wild-type and attenuated strains without
reported serious adverse events (Table 1) [19–25]. Insights into
the influence of route of infection, incubation periods, durations
of protective immunity and viral shedding were gained from these
studies, but until recently limitations in technology have meant
smaller contributions to understanding of immuno-pathogenesis
or facilitating the development of effective vaccines. Previous
human RSV challenge studies used viruses (e.g. Long and A2) iso-
lated by serial laboratory passage in multiple cell lines or live-
attenuated strains. Successful infection required the use of very
high doses and were often minimally symptomatic, suggesting that
these viral strains had been extensively laboratory-adapted and
even so-called wild-type strains were likely attenuated [25,26].Please cite this article in press as: Habibi MS, Chiu C. Controlled human infectio
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so differ somewhat from currently circulating RSV strains, thus
affecting the applicability of those findings to modern infection.
Also, it has been difficult to ensure consistency between stocks in
different laboratories. Together, these issues have posed a problem
when extrapolating these historical data to understanding of natu-
ral infection, and raise some uncertainties over the generalisability
of some findings.4. The contemporary human RSV challenge model
More recently, a wild-type, low-passage strain of RSV A has
been produced according to Good Manufacturing Practice (GMP)
guidelines specifically for human challenge. The progenitor virus,
RSV Memphis 37 (M37), was isolated from a child with bronchioli-
tis in 2006 [27]. RSV M37 was grown to high titre in Vero cell cul-
ture and individual lots tested extensively for the presence of
adventitious agents. While GMP challenge pathogens are generally
considered the standard for human experimental infections, in the
UK and EU there are no specific regulations that stipulate a require-
ment for GMP manufacture. Instead, if sufficient testing for adven-
titious agents can be demonstrated, GMP manufacturing may not
be required. Nevertheless, worldwide this is not generally true
and in any case, the costs incurred in producing a GMP virus are
in large part related to the testing, so are not greatly reduced by
pursuing the non-GMP path [28].
The first published study using this virus in humans was by
Zaas et al. in 2009 [29]. The objective was to identify a peripheral
blood mRNA signature to diagnose acute respiratory viral infection.
Nine out of twenty subjects challenged became infected and, while
the baseline characteristics of the subjects and course of the illness
were not described in detail, it was noted that symptoms peaked at
a median 141.5 h post-inoculation. Transcriptomic analysis of
whole blood identified a transcriptional signature associated with
respiratory viral infection that distinguished symptomatically
infected from uninfected individuals as well as those with bacterial
infection with at least 93% accuracy. The following year DeVin-
cenzo et al. [30] reported on a dose-ranging study involving
thirty-five healthy adults challenged intranasally with increasing
doses of RSV M37 from 3.0 to 5.4 log10 PFU mL1. Unlike the earlier
study, subjects were screened so that only individuals with serum
RSV neutralising antibody titres in the lower third of those tested
were enrolled. The key findings were an infection rate of 77% with
no statistical differences in infection rate for different inoculating
doses; a dose of 4 log10 PFU mL1 has since been commonly used
as the standard inoculum. The incubation period was 3.1 days
and virus was shed for a mean of 7.4 days. Viral load and symp-
toms peaked around day 6 post-inoculation and a significant corre-
lation was observed between viral load and respiratory tract
symptom scores. These findings have been consistent in subse-
quent studies including those that we performed several years
later with the same virus, indicating the stability of the stock and
the clinical syndrome it causes (Fig. 1). Additionally, nasal lavage
concentrations of tumour necrosis factor (TNF), interleukin (IL) 6,
IL8, and macrophage inflammatory protein (MIP) 1a were noted
as biomarkers of clinical disease and a significant positive correla-
tion was observed between cumulative nasal IL6 levels and cumu-
lative viral load. The authors concluded that viral load was the
main driver of clinical disease and the study therefore proposed
a model by which to demonstrate that antiviral activity by a drug
or reduction in virus titre by vaccine-induced immunity could
reduce RSV-associated illness.
RSV M37 is currently one of only two GMP strains available for
human challenge. It has been shown to consistently cause mild and
moderate disease with a relatively high attack rate even if volun-n with RSV: The opportunities of experimental challenge. Vaccine (2016),
4 M.S. Habibi, C. Chiu / Vaccine xxx (2016) xxx–xxxteers are not selected on the basis of low serum antibody titres. The
other, a GMP virus made by reverse genetics using the sequence of
the laboratory RSV A2 strain, has recently been developed and the
first study using it is currently underway (ClinicalTrials.gov identi-
fier NCT02484417). However, as time progresses, these strains may
become outdated as new RSV strains (such as currently circulating
RSV A ON1 and RSV B BA strains that contain 60–72 nucleotide
duplications in the attachment G protein) emerge and come to pre-
dominate globally [31,32].
5. Challenge models enable proof-of-concept for RSV antiviral
development
The RSV M37 model as established by DeVincenzo has since
been employed in a number of clinical studies as early proof-of-
concept for directly acting antiviral drugs. This model was used
to study 141 healthy volunteers who were randomised to receive
the novel oral RSV fusion inhibitor GS5806 or placebo either on
the first day of detectable viral shedding in nasal lavage or day 5
post-inoculation (whichever was earlier) [33]. Participants treated
with GS-5806 had significantly decreased lower mean cumulative
viral load by area-under-the curve (AUC), lower mean AUC change
from baseline symptom score and lower total mucus weight than
those treated with placebo. No serious adverse events were
reported. Recently, a second novel compound, ALS-008176, an orala
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Fig. 1. Viral load and symptoms following experimental infection of 61 volunteers wit
PFU mL1 of RSV Memphis 37. (a) Viral load was measured daily by qPCR of nasal lavage.
deemed infected following inoculation are shown in red, those deemed uninfected are s
and symptoms is shown for infected individuals. (For interpretation of the references to
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http://dx.doi.org/10.1016/j.vaccine.2016.08.086prodrug of a cytidine nucleoside analogue that inhibits RSV poly-
merase, was evaluated in 62 healthy adults with low serum RSV
neutralising antibody titres using experimental challenge with
RSV M37 [34]. ALS-008176 appeared possibly even more potent
than GS-5806, achieving a more rapid reduction in viral load and
had a higher theoretical genetic barrier to resistance; however,
the authors conceded that the sample sizes were too small to con-
clude any definite difference. Whilst both these studies were only
intended as a proofs-of-concept, GS-5806 and ALS-008176 repre-
sent a significant advance in RSV antiviral research and demon-
strate the power of human experimental challenge in
accelerating development of novel treatments for RSV infection.
A second lot of RSV M37 was acquired by Alnylam Pharmaceu-
ticals to test the efficacy of a small interfering RNA (siRNA) directed
against the mRNA of RSV N protein [35]. Although a trend was seen
in the ALN-RSV01-treated group toward a lower viral load, the
study was not powered to detect a statistically significant differ-
ence. As one of the only examples of RNA interference (RNAi) as
a human therapeutic, again the use of experimental human chal-
lenge proved crucial as proof-of-concept.
Together these studies highlight the strengths of experimental
challenge as a platform for early tests of efficacy for RSV therapeu-
tics. The primary outcome of reduced viral load offers a clear and
definitive target measure to enable go/no-go decisions using rela-
tively small numbers of study subjects. It remains to be seenb
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M.S. Habibi, C. Chiu / Vaccine xxx (2016) xxx–xxx 5whether lowering of viral load to this extent is associated with
clinical benefit in severely ill individuals, and indeed whether this
degree of viral load reduction can even be achieved in the hospi-
talised individuals where treatment may be started late. The test-
ing of antivirals is also arguably a more straightforward problem
than that of vaccines. Understanding of the mode of action of the
antiviral coupled with the ability to deliver it at an optimum time
and dosage in relation to infection all help to optimise the model.
In contrast, the development of vaccines against RSV involves sub-
stantially more complexity, with the nature of the vaccine; the
type, level, timing and anatomical site of the immunity induced;
and the interaction of host immunity (both pre-existing and
vaccine-induced) with infecting virus all playing a role and where
absolute protection or significant reductions in viral load may not
be the only definitions of success.Nasal anti−RSV−IgA (log2 titre)
Fig. 2. RSV-specific nasal IgA titres correlate with protection from PCR-confirmed
infection. Sixty-one healthy young adults were inoculated with RSV Memphis 37.
RSV-specific nasal IgA end-point titres were measured in nasal washes by ELISA and
normalised using relative urea concentrations in nasal lavage and serum. Logistic
regression was achieved by a generalised linear model using a binomial (logit) link
function in R. Odds ratio and 95% confidence intervals (blue) are shown.
Figure adapted from Habibi et al. [42]. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)6. Experimental challenge provides insights into pathogenesis
Despite the delays and setbacks that have affected the RSV vac-
cine field, the potentially enormous positive impact of effective
RSV vaccines that can protect infants and/or frail elderly adults
has continued to drive development, with over 50 vaccine candi-
dates currently recognised [36]. In most other infectious diseases,
successful vaccines have been developed empirically, without the
a priori need to understand the true mechanism of protection but
requiring defined measurable correlates of protection to predict
efficacy [37]. However, predicting risk of infection based on
immune correlates has been difficult to achieve in RSV, which
induces only modest and transient immunity meaning that every-
one remains susceptible throughout life despite relatively minor
viral antigenic variation. This was demonstrated in historical RSV
challenge studies, where re-infection by an identical strain through
serial re-challenge of a cohort of infected volunteers every
2 months led to approximately 20% of subjects becoming re-
infected on each occasion [24]. The partial immunity induced by
RSV and resultant lack of individuals who are consistently pro-
tected against infection or disease have therefore made robust cor-
relates of protection difficult to clearly determine in population-
based studies.
Almost all successful vaccines rely on the generation of high
titres of functional pathogen-specific antibodies as correlates of
protection [38]. In RSV, serum neutralising antibody titres have
been shown to negatively correlate with risk of medical attendance
with RSV disease but no upper threshold of protection has been
identifiable, with serum neutralising antibodies only broadly
dividing individuals into those with minimal antibody (and there-
fore highly susceptible) and those with adult-like levels [39]. Pre-
vious observational studies indicated that local RSV-specific
antibodies might be better correlates of protection but suggested
that protective antibody levels were not well maintained [40,41].
To address these questions, we used the experimental human
infection system to study the relationship between pre-existing
local and systemic antibodies with infection [42]. No selection of
subjects was made on the basis of pre-existing antibody levels
and, among these highly immunologically experienced individuals,
approximately 56% become infected following experimental chal-
lenge. Thus, while almost all had relatively high levels of serum
neutralising antibody, some were still susceptible to infection
while others were apparently immune. Serum neutralising anti-
bodies by plaque-reduction neutralisation assay only loosely corre-
lated with protection from PCR-confirmed infection. Instead, we
found local mucosal RSV-specific IgA to be significantly more
robustly predictive (Fig. 2). Measurement of RSV-specific IgA in
respiratory samples have proved technically problematic in the
field, with wide variability depending on the consistency of sam-Please cite this article in press as: Habibi MS, Chiu C. Controlled human infectio
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model and ability to normalise using comparative urea concentra-
tions in nasal lavage and serum. Nevertheless, these data showed
that RSV infection was poorly immunogenic and only 21% of sub-
jects studied were predicted to haveP80% protection on the basis
of nasal IgA levels induced even 4 weeks following infection. Fur-
thermore, both serum and nasal antibody levels waned to pre-
infection levels within 6 months. Analysis of peripheral blood
memory B cells (MBCs) revealed an RSV-specific defect in the
induction of anti-RSV IgA-secreting MBCs, which for the first time
provided a possible explanation of why the natural immune
response to RSV does not induce lasting protection from reinfec-
tion. These findings suggest that induction of mucosal antibodies
may be more effective in preventing RSV infection compared with
serum IgG, which might have a preferential role in preventing
lower respiratory disease. However, these vaccines must also
improve upon naturally-induced anti-RSV immunity by inducing
higher antibody titres and circumventing any specific defect in
the RSV-specific memory response.
Antibodies can protect against infection but once infection has
occurred, they have little role in reducing disease severity
[49,50]. Many licensed vaccines, such as those against influenza,
remain suboptimal in inducing persistently high levels of antibody,
particularly in age groups such as the elderly and young children.
The likelihood of infection occurring in spite of having been vacci-
nated against RSV will therefore be substantial. T cell-inducing
vaccines have a number of theoretical advantages, including the
amelioration of disease if infection does occur; the potential to pro-
tect against multiple strains of the same virus in the face of some
antigenic change; and helping B cells produce high affinity anti-
bodies [43]. However, in primary RSV infection, T cells arise late
and are not thought to contribute significantly to protection [7].
Furthermore, in mouse models they have been shown to cause
immunopathology [44]. While most clinical studies have relied
on peripheral blood to analyse T cell responses, animal models
have highlighted the unique immunobiology of T cells in the lung.
Until recently, it has not been possible to systematically study
these in the context of acute RSV infection to clarify their impor-
tance and role.
We recently investigated the role of virus-specific T cells in RSV
infection in the experimental human infection model [17]. Using
MHC-peptide tetramers, we labelled and tracked RSV-specificn with RSV: The opportunities of experimental challenge. Vaccine (2016),
6 M.S. Habibi, C. Chiu / Vaccine xxx (2016) xxx–xxxCD8+ T cells in blood and airways of experimentally infected vol-
unteers, sampling the lower airway by bronchoscopy. We showed
that RSV-specific CD8+ T cells are significantly more abundant in
the airway compared with peripheral blood and almost all display
the characteristic phenotypic markers (CD69 and CD103) of resi-
dent memory T (Trm) cells. Trm cells are a recently described
memory T cell subset that are generated at sites of pathogen entry
and remain at those sites poised to respond rapidly on re-infection
[45]. They have been shown not only to clear infection but also
coordinate the early recall response by recognition of antigen
and cytokine production in an innate-like manner, altering the
inflammatory environment to further recruit other memory T cells
[46]. Thus, they are highly specialised to confer early protection,
have been shown to provide heterosubtypic immunity against
multiple strains of influenza and are strong candidates for the
enhancement of vaccine-mediated immunity [47].
In the experimental human infection model, the frequency of
RSV-specific CD8+ T cells in the airway (but not peripheral blood)
prior to infection correlated with reduction in symptom severity
and viral load on subsequent infection [17]. They were generated
at extremely high frequencies during acute infection and contin-
ued to accumulate well into convalescence. However, they were
relatively poor producers of cytotoxic molecules such as granzyme
B and perforin, and together with an observed deficiency in pro-
duction of type 1 cytokines by RSV-specific CD8+ T cells in blood
compared to influenza, these data again suggest that RSV-specific
adaptive immune responses are relatively impaired. Several RSV
vaccine candidates have been developed that can be delivered
intranasally with the aim of inducing both antibodies and T cells
in the respiratory tract [48,49]. However, the development of
Trm cells has not been investigated using any of these. Further-
more, little is yet known about the specificities and functional
capacity of CD4+ T cells in human RSV. These remain important
research avenues that must be explored to further understand
optimal vaccination.7. Limitations of studies of healthy young adults
While experimental human infections benefit from being con-
ducted in the natural host of RSV in a controlled fashion, there
remain a number of limitations. Practical and ethical hurdles have
been discussed earlier but a fundamental limitation exists in
studying healthy adults who only suffer mild-to-moderate disease,
while severe complications of RSV mostly occur in high-risk peo-
ple. Adult humans represent an immunologically mature and
highly RSV-experienced population so the induced disease and
observed host responses will inevitably differ from those in bron-
chiolitis of infants [50]. Extrapolating into that population should
therefore be made with caution. Nevertheless, the heterogeneity
of clinical outcome following experimental infection of healthy
adults does facilitate the inference of protective immune mecha-
nisms that may be universally applicable. Furthermore, whilst we
must accept that deliberately infecting an infant or high-risk adult
could never be justified ethically or scientifically, experimental rhi-
novirus colds have been safely induced in adults with mild COPD
and moderate asthma [13,14]. It may therefore not be unreason-
able to enrol healthy elderly persons in experimental studies with
RSV with careful screening and safety considerations addressed.
Adults pre-screened for especially low serum neutralising anti-
bodies do have a greater probability of developing a common-cold
illness, making them an ideal group in which to demonstrate effi-
cacy of antivirals, in which the increased attack rate allows reduc-
tion in sample size. However, it might be argued that these people
are an unusual population group and particularly susceptible to
RSV among adults, either due to lack of recent natural exposurePlease cite this article in press as: Habibi MS, Chiu C. Controlled human infecti
http://dx.doi.org/10.1016/j.vaccine.2016.08.086or some intrinsic vulnerability. Extrapolation of study endpoints
in these groups to other, more immunologically-experienced indi-
viduals, such as the elderly, may underestimate the contribution of
the host response. Therefore, it may necessary to accept the
increased cost associated with larger sample sizes to power a vac-
cine challenge study sufficiently to detect statistically significant
efficacy in more immunologically representative cohorts.
Successful human infection studies depend on the availability
of well-characterised and standardised viral inocula. Although
there is no current legal requirement for viral inocula to be pre-
pared in accordance with Good Manufacturing Practice (GMP) in
the EU it remains highly desirable to ensure comparability across
studies and the safety of participants. Unfortunately, the creation
of new and alternate GMP viruses will be time-consuming and
costly, with a capital outlay that may be beyond most academic
groups. This issue is not limited to RSV and is a major hurdle to
the expansion of human infection challenge research in general
[10]. Further cooperation between funders and consortia of exper-
imental human infection researchers are likely to be required to
enhance the sustainability of all these models in the face of these
requirements by sharing of knowledge and infrastructure.
8. Conclusion
Experimental human infection with RSV has already provided
proof-of-concept for therapeutics and furthered our understanding
of the pathogenesis of the disease. Thus far, no group has published
a study evaluating a potential RSV vaccine using this model but, in
spite of its limitations, it is likely to be a powerful system in which
to do so, given the high attack rate of at least 50% of unselected
adults. Experimental human infection with RSV therefore offers a
unique and vital opportunity to test antivirals, vaccines, and novel
therapeutics, streamlining successful development and exploring
mechanisms of pathogenesis of this enigmatic virus in the natural
host. Industry and academic groups need to join forces to over-
come the considerable tasks of the creation and maintenance of
challenge agents as well as the logistics of quarantine in order to
maintain the utility of these models, which will be essential in
maintaining the momentum currently seen in RSV vaccine
research.
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